Submitted by Anonymous (not verified) on 29 November 2023 - 10:41
Human medicines European public assessment report (EPAR): MabThera, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 02/06/1998, Revision: 60, Status: Authorised
Source: